ArticleClinical ophthalmology (Auckland, N.Z.)2025
Visual Outcomes Following Hyperbaric Oxygen Therapy in Acute Central Retinal Artery Occlusion Patients.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Perioperative central retinal artery occlusion after prone posterior cervical spine surgery treated with delayed hyperbaric oxygen therapy: a case report and targeted literature review.BMC anesthesiology · 2026Review
- Exploring hyperbaric oxygen therapy for central retinal artery occlusion beyond 24 h: case report.Therapeutic advances in ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy of a novel HBOT protocol, characterized by specific pressure levels and treatment duration in patients with CRAO patients presenting within 24 hours, compared to a non-HBOT cohort. Patients and methods: This retrospective cohort study included patients diagnosed with CRAO presenting within 24 hours from October 2003 to March 2022. Patients treated with intravenous recombinant tissue plasminogen activator (rt-PA) or experiencing treatment-related visual complications were excluded. Of 49 eligible patients, 17 underwent HBOT following the novel protocol, while 32 received standard care (non-HBOT). Results: Baseline logMAR VA was 2.3 in both groups. At discharge, 76.5% of the HBOT group exhibited a VA improvement of at least 0.3 logMAR, compared to 40.6% in the non-HBOT group (p = 0.02). Mean logMAR VA at discharge was 1.4 ± 0.8 in the HBOT group and 2.0 ± 0.8 in the non-HBOT group. After one month, the mean logMAR VA remained at 1.4 ± 0.9 in the HBOT group and was 1.9 ± 0.9 in the non-HBOT group. Conclusion: While constrained by the small sample size and short-term outcome data, these results showed the benefits of this unique HBOT protocol in CRAO presenting within the critical 24-hour window. Nevertheless, further prospective validation is necessary before widespread clinical adoption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.